MX2016013969A - Compuestos heteroaromaticos y su uso como ligandos de dopamina d1. - Google Patents
Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.Info
- Publication number
- MX2016013969A MX2016013969A MX2016013969A MX2016013969A MX2016013969A MX 2016013969 A MX2016013969 A MX 2016013969A MX 2016013969 A MX2016013969 A MX 2016013969A MX 2016013969 A MX2016013969 A MX 2016013969A MX 2016013969 A MX2016013969 A MX 2016013969A
- Authority
- MX
- Mexico
- Prior art keywords
- dopamine
- ligands
- compounds
- heteroaromatic compounds
- schizophrenia
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000001050 pharmacotherapy Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Abstract
La presente invención proporciona, en parte, compuestos de la Fórmula I: (ver Fórmula) y las sales de éstos aceptables desde el punto de vista farmacéutico; procesos para la preparación de; intermediarios usados en la preparación de; y composiciones que contienen estos compuestos o sales, y sus usos para tratar trastornos mediados por D1 (o asociados a D1) que incluyen, por ejemplo, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), trastorno esquizotípico de la personalidad, deficiencia cognitiva (por ejemplo, deficiencia cognitiva asociada a esquizofrenia, AD, PD o tratamiento de farmacoterapia), ADHD, enfermedad de Parkinson, ansiedad y depresión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984079P | 2014-04-25 | 2014-04-25 | |
| PCT/IB2015/052604 WO2015162516A1 (en) | 2014-04-25 | 2015-04-09 | Heteroaromatic compounds and their use as dopamine d1 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013969A true MX2016013969A (es) | 2017-01-11 |
Family
ID=53276921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013969A MX2016013969A (es) | 2014-04-25 | 2015-04-09 | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9540352B2 (es) |
| EP (1) | EP3134404A1 (es) |
| JP (1) | JP6239149B2 (es) |
| KR (1) | KR20160142402A (es) |
| CN (1) | CN107074843A (es) |
| AP (1) | AP2016009512A0 (es) |
| AU (1) | AU2015249497A1 (es) |
| BR (1) | BR112016023740A2 (es) |
| CA (1) | CA2946475A1 (es) |
| CL (1) | CL2016002677A1 (es) |
| CR (1) | CR20160494A (es) |
| CU (1) | CU20160156A7 (es) |
| DO (1) | DOP2016000289A (es) |
| EA (1) | EA201691788A1 (es) |
| IL (1) | IL248132A0 (es) |
| MA (1) | MA39914A (es) |
| MD (1) | MD20160109A2 (es) |
| MX (1) | MX2016013969A (es) |
| NI (1) | NI201600161A (es) |
| PE (1) | PE20170009A1 (es) |
| PH (1) | PH12016501993A1 (es) |
| SG (1) | SG11201608468TA (es) |
| SV (1) | SV2016005305A (es) |
| TN (1) | TN2016000447A1 (es) |
| TW (1) | TWI561517B (es) |
| WO (1) | WO2015162516A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CN106232118A (zh) * | 2014-04-25 | 2016-12-14 | 辉瑞大药厂 | 杂芳族化合物及其作为多巴胺d1配体的用途 |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| EP3137469B1 (en) | 2014-04-28 | 2019-10-09 | Pfizer Inc | Heterocyclic compounds and their use as dopamine d1 ligands |
| US11440898B2 (en) | 2016-12-28 | 2022-09-13 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN117177973A (zh) | 2021-04-19 | 2023-12-05 | 蒙特利尔大学 | 吡啶并[3,2-d]嘧啶化合物及其用于治疗增殖性疾病的用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145272A (ja) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体 |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2004510712A (ja) | 2000-09-22 | 2004-04-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | オクタヒドロ−インドリジンおよびキノリジンおよびヘキサヒドロ−ピロリジン |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| CA2615420A1 (en) * | 2005-07-15 | 2007-01-25 | 4Sc Ag | 2-arylbenzothiazoles and uses thereof |
| JP2010509392A (ja) * | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
| PE20110834A1 (es) * | 2008-12-06 | 2011-12-14 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) |
| JP2012516847A (ja) * | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｋｔ活性の阻害剤 |
| JP5883399B2 (ja) * | 2010-02-11 | 2016-03-15 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 |
| US9309199B2 (en) * | 2010-03-04 | 2016-04-12 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
| WO2011119894A2 (en) * | 2010-03-24 | 2011-09-29 | Kinagen, Inc | Heterocyclic compounds useful for kinase inhibition |
| CN102558147B (zh) | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| JP5857168B2 (ja) | 2012-11-08 | 2016-02-10 | ファイザー・インク | ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用 |
| EA201500402A1 (ru) | 2012-11-08 | 2016-05-31 | Пфайзер Инк. | Гетероароматические соединения в качестве лигандов допамина d1 |
| CN102964340B (zh) * | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
| TN2015000547A1 (fr) * | 2013-06-27 | 2017-04-06 | Pfizer | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 |
| CN106232118A (zh) | 2014-04-25 | 2016-12-14 | 辉瑞大药厂 | 杂芳族化合物及其作为多巴胺d1配体的用途 |
| WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP3137469B1 (en) | 2014-04-28 | 2019-10-09 | Pfizer Inc | Heterocyclic compounds and their use as dopamine d1 ligands |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
-
2015
- 2015-04-09 CA CA2946475A patent/CA2946475A1/en not_active Abandoned
- 2015-04-09 EA EA201691788A patent/EA201691788A1/ru unknown
- 2015-04-09 PE PE2016002126A patent/PE20170009A1/es not_active Application Discontinuation
- 2015-04-09 KR KR1020167032884A patent/KR20160142402A/ko not_active Withdrawn
- 2015-04-09 MX MX2016013969A patent/MX2016013969A/es unknown
- 2015-04-09 JP JP2016564000A patent/JP6239149B2/ja not_active Expired - Fee Related
- 2015-04-09 BR BR112016023740A patent/BR112016023740A2/pt not_active IP Right Cessation
- 2015-04-09 CN CN201580021950.5A patent/CN107074843A/zh active Pending
- 2015-04-09 TN TN2016000447A patent/TN2016000447A1/en unknown
- 2015-04-09 MD MDA20160109A patent/MD20160109A2/ro not_active Application Discontinuation
- 2015-04-09 AP AP2016009512A patent/AP2016009512A0/en unknown
- 2015-04-09 EP EP15726685.9A patent/EP3134404A1/en not_active Withdrawn
- 2015-04-09 MA MA039914A patent/MA39914A/fr unknown
- 2015-04-09 SG SG11201608468TA patent/SG11201608468TA/en unknown
- 2015-04-09 WO PCT/IB2015/052604 patent/WO2015162516A1/en not_active Ceased
- 2015-04-09 CR CR20160494A patent/CR20160494A/es unknown
- 2015-04-09 AU AU2015249497A patent/AU2015249497A1/en not_active Abandoned
- 2015-04-22 TW TW104112874A patent/TWI561517B/zh not_active IP Right Cessation
- 2015-04-23 US US14/694,333 patent/US9540352B2/en active Active
-
2016
- 2016-03-22 US US15/077,229 patent/US9850232B2/en active Active
- 2016-09-29 IL IL248132A patent/IL248132A0/en unknown
- 2016-10-07 PH PH12016501993A patent/PH12016501993A1/en unknown
- 2016-10-20 CL CL2016002677A patent/CL2016002677A1/es unknown
- 2016-10-21 NI NI201600161A patent/NI201600161A/es unknown
- 2016-10-24 CU CUP2016000156A patent/CU20160156A7/es unknown
- 2016-10-25 SV SV2016005305A patent/SV2016005305A/es unknown
- 2016-10-25 DO DO2016000289A patent/DOP2016000289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SV2016005305A (es) | 2017-07-19 |
| TWI561517B (en) | 2016-12-11 |
| KR20160142402A (ko) | 2016-12-12 |
| US20160200711A1 (en) | 2016-07-14 |
| WO2015162516A1 (en) | 2015-10-29 |
| IL248132A0 (en) | 2016-11-30 |
| AU2015249497A1 (en) | 2016-10-20 |
| CU20160156A7 (es) | 2017-02-02 |
| CL2016002677A1 (es) | 2017-02-10 |
| EP3134404A1 (en) | 2017-03-01 |
| CR20160494A (es) | 2016-12-20 |
| SG11201608468TA (en) | 2016-11-29 |
| US20150307494A1 (en) | 2015-10-29 |
| TW201604188A (zh) | 2016-02-01 |
| US9540352B2 (en) | 2017-01-10 |
| DOP2016000289A (es) | 2017-02-15 |
| PE20170009A1 (es) | 2017-03-17 |
| EA201691788A1 (ru) | 2017-03-31 |
| JP6239149B2 (ja) | 2017-11-29 |
| AP2016009512A0 (en) | 2016-10-31 |
| US9850232B2 (en) | 2017-12-26 |
| JP2017513881A (ja) | 2017-06-01 |
| CA2946475A1 (en) | 2015-10-29 |
| NI201600161A (es) | 2016-11-25 |
| CN107074843A (zh) | 2017-08-18 |
| MD20160109A2 (ro) | 2017-04-30 |
| PH12016501993A1 (en) | 2017-01-09 |
| MA39914A (fr) | 2017-03-01 |
| BR112016023740A2 (pt) | 2017-08-15 |
| TN2016000447A1 (en) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| IN2014DN09826A (es) | ||
| CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. | |
| CL2008003138A1 (es) | Compuestos derivados de 6-(alcoxi o fenilalcoxi)-indan-1-alquil aminas aciladas; composicion farmaceutica; y uso para el tratamiento o prevencion de alteraciones melatoninergicos tales como depresion, alteraciones del sueno, diabetes, parkinson y enfermedad de alzheimer. | |
| EA201491291A1 (ru) | АГОНИСТЫ mGlu 2/3 | |
| IN2013MU03838A (es) |